Literature DB >> 12168992

Human gene therapy and the slippery slope argument.

Veikko Launis1.   

Abstract

The article investigates the validity of two different versions of the slippery slope argument construed in relation to human gene therapy: the empirical and the conceptual argument. The empirical version holds that our accepting somatic cell therapy will eventually cause our accepting eugenic medical goals. The conceptual version holds that we are logically committed to accepting such goals once we have accepted somatic cell therapy. It is argued that neither the empirical nor the conceptual version of the argument can provide a conclusive moral reason for banning somatic cell therapy. According to a third interpretation, referred to as the arbitrary result argument, the many apparent similarities between somatic cell therapy and eugenic-based human genetic engineering drive us to make principled choices concerning what differences and similarities between the two practices should be regarded as morally (ir)relevant. Decisions of this kind are likely to have unpredictable moral consequences. Thus formulated, the slippery slope argument has much plausibility. One objects to somatic cell therapy not so much because of what is at the bottom of the slope on which it lies, but because it is on a slope of which one does not know what is at the bottom. While the arbitrary result argument does not provide a conclusive reason for prohibiting human gene therapy, it reminds of a very important thing: when making bioethical decisions, we should be as specific and as consistent as possible about our basic moral and medical concepts.

Entities:  

Keywords:  Analytical Approach; Genetics and Reproduction; Philosophical Approach

Mesh:

Year:  2002        PMID: 12168992     DOI: 10.1023/a:1016052122403

Source DB:  PubMed          Journal:  Med Health Care Philos        ISSN: 1386-7423


  15 in total

1.  [Attitudes toward genetic testing in Finland].

Authors:  P Aula; M Hietala; P Niemelä; A R Aro; A Hakonen; L Peltonen
Journal:  Duodecim       Date:  1996

2.  The recombinant DNA debate.

Authors:  Stephen P Stich
Journal:  Philos Public Aff       Date:  1978

3.  Human germ-line therapy: the case for its development and use.

Authors:  B K Zimmerman
Journal:  J Med Philos       Date:  1991-12

4.  Can enhancement be distinguished from prevention in genetic medicine?

Authors:  E T Juengst
Journal:  J Med Philos       Date:  1997-04

5.  Human gene therapy and slippery slope arguments.

Authors:  T McGleenan
Journal:  J Med Ethics       Date:  1995-12       Impact factor: 2.903

6.  The slow road to gene therapy.

Authors:  D J Weatherall
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

7.  Public attitudes towards the selection of desirable characteristics in children.

Authors:  T Marteau; S Michie; H Drake; M Bobrow
Journal:  J Med Genet       Date:  1995-10       Impact factor: 6.318

8.  Genetic disorders and the ethical status of germ-line gene therapy.

Authors:  E M Berger; B M Gert
Journal:  J Med Philos       Date:  1991-12

9.  Debunking the slippery slope argument against human germ-line gene therapy.

Authors:  D Resnik
Journal:  J Med Philos       Date:  1994-02

10.  Attitudes toward genetic testing among the general population and relatives of patients with a severe genetic disease: a survey from Finland.

Authors:  M Hietala; A Hakonen; A R Aro; P Niemelä; L Peltonen; P Aula
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

View more
  3 in total

1.  Intertemporal Disagreement and Empirical Slippery Slope Arguments.

Authors:  Thomas Douglas
Journal:  Utilitas       Date:  2010-06

2.  The Slippery Slope Argument in the Ethical Debate on Genetic Engineering of Humans.

Authors:  Douglas Walton
Journal:  Sci Eng Ethics       Date:  2016-12-20       Impact factor: 3.525

3.  Value-impregnated factual claims and slippery-slope arguments.

Authors:  Gert Helgesson; Niels Lynøe; Niklas Juth
Journal:  Med Health Care Philos       Date:  2017-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.